Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...

MONTREAL, April 14, 2025 /CNW/ - Novartis Canada is pleased to announce that Fabhalta ® (iptacopan capsules) is now available across Canada for adult patients with paroxysmal nocturnal ...

The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Novartis’ kidney disease troika keeps marching forward. With a new FDA approval, the company’s Fabhalta has become the first treatment endorsed by the agency for the ultrarare kidney disease ...

The FDA has approved Novartis’ Fabhalta (iptacopan) as the first and only treatment for C3 glomerulopathy (C3G). Previously, patients with C3G were forced to rely on supportive care and broad ...

Novartis’ oral Fabhalta (iptacopan) has been approved by the US Food and Drug Administration (FDA) as the first treatment for the ultra-rare kidney disease complement 3 glomerulopathy (C3G). Every ...

Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...

Novartis announced that oral Fabhalta (iptacopan) has received US Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...